R&D performance varies widely… Fewer novel therapies seem to be coming from the drug industry as a whole. What is not generally recognized is how much firms differ in performance and (perhaps) why. This Lehman analysis shocked many but confirmed that some firms were either “lucky” or were somehow “better designed”. Later analyses suggest it is their “R&D Architecture”; what new capabilities are designed-in, that makes the difference. See this 2010 McKinsey article on where those “value levers” are.
This site examines what firms have employed to get even farther ahead. Some of these “sea-changes” are still very relevant to the future, other hot ideas are creating new value and advantages for the next five years. Let’s explore what leaders are doing to stay far ahead of median performance. More…
Key Advances in R&D Returns:
|
|
|
Automating Serendipity in Pharma R&D
Long ago, many felt that discovering and launching drugs required insight, expertise and not a small bt of “serendipity”. Others felt that winners were somehow just lucky… Some firms decided to make their own luck. Some lessons and principles: |
Falling behind competitors w/ Semantics?
If you are trying to compete with only 20% of the information your competitors can access, no wonder they are finding the choice in-licensing and disease targets. But many firms are confused by software and consultant hype. A more rational approach…
|
Well designed blog and I’m stunned by the first graph. I plan to return many times to learn more about how organizations can get away from this black hole sense.
Ed
I find this article on innovation and how to “measure” it provocative:
http://globalpublicsquare.blogs.cnn.com/2011/06/08/how-to-measure-innovation/?hpt=hp_bn2
Consider the statement there that Apple spends about 1/5th of Microsoft as a % of revenues on innovation… How might that guide firms like Pharma and what makes such a difference ? Pure R&D spend is of course a bad metric of “innovation productivity” or ROI. On the other hand the article suggests that a “larger city” is more innovative – the opposite of what we seem to see in industry. Others’ perspectives?